The Market Opportunity
China’s healthcare sector is undergoing rapid transformation. By 2030, national healthcare expenditure is projected to reach £18 trillion, with the healthcare providers market growing to US$1.10 trillion in 2025. By 2040, 28% of China’s population will be over 60, amplifying demand for chronic disease care, elder services, and digital-first solutions—sectors where UK expertise is widely respected.
Priority Funding Areas
The newly released funding will support:
- Infectious disease control (including HIV/AIDS and tuberculosis)
- Chronic disease prevention and management
- Expansion of mental health services
- Immunisation programmes
- Digital health infrastructure
UK companies are especially well-positioned to offer:
- AI-enabled diagnostics and point-of-care testing
- Telemedicine platforms and patient engagement tools
- Healthcare analytics and outcomes-based monitoring systems
Access Simplified: Market Entry Reforms
China’s regulatory landscape now offers several entry points:
- Wholly foreign-owned hospitals permitted in nine major cities, including Beijing, Shanghai, Shenzhen, and Guangzhou
- Foreign-led R&D in stem cells, gene therapy, and diagnostics permitted in Free Trade Zones (FTZs) across Beijing, Shanghai, Guangdong, and Hainan
- Fast-track drug approval pathways allow rapid registration for innovative products
Innovation & Investment Climate
China’s AI healthcare market is booming, projected to grow from US$1.6 billion in 2023 to US$16 billion by 2028, fuelled by centralised data, EMR interoperability, and supportive regulation. Innovative drug equities have outperformed global peers, reflecting strong investor confidence and a robust appetite for international partnerships.
What UK Companies Should Do — Now, Not Later
- Assess Market Fit Align your product and expertise—particularly in chronic disease, eldercare, and digital health—with China’s policy priorities and demographic needs.
- Build Strategic Partnerships Collaborate with Chinese hospitals, research institutes, and digital health platforms that possess necessary regulatory status and local access.
- Navigate Regulatory Pathways Gain familiarity with China’s evolving regulatory environment, FTZ-specific rules, data localisation protocols, and IP frameworks.
- Pilot Marketable Projects Launch proof-of-concept initiatives eligible for co-funding—ideal for building stakeholder trust and testing commercial viability.
- Refine Value Propositions Tailor your offerings to address China’s unique challenges, such as rural-urban health disparities and digital engagement with older populations.
- Engage Key Stakeholders Establish relationships with relevant ministries, industry bodies, and associations to stay ahead of upcoming tenders and policy shifts.
EFEC: Your UK-China Partner from Strategy to Implementation
Excellence First Enterprise Consultancy (EFEC) is committed to walking alongside UK life sciences companies as they enter and grow within the Chinese market. Through our In2China advisory platform, we provide hands-on support — from policy alignment and partnership development to regulatory navigation and in-country execution.
With nearly two decades of UK-China collaboration experience, EFEC doesn’t just advise from afar — we accompany our clients, build bridges with local stakeholders, and remain engaged throughout each phase of market expansion. Our expertise and networks ensure that UK companies not only enter the Chinese healthcare market — they thrive in it.
References & Further Reading
- China Ministry of Finance – 2025 Major Public Health Service Subsidy Fund Announcement (Chinese)
- National Health Commission – 2025 Basic Public Health Service Guidance (Chinese)
- UK Department for Business and Trade – Doing Business in China: Healthcare Sector
- China Briefing – Entering China’s Healthcare Market: 2024/2025 Guide
- Deloitte China – 2025 China Healthcare Industry Outlook (English)
